{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:24:51Z","timestamp":1789601091266,"version":"build-2803163510"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007787","name":"National Research Centre","doi-asserted-by":"publisher","award":["12060101"],"award-info":[{"award-number":["12060101"]}],"id":[{"id":"10.13039\/100007787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.bioorg.2021.105466","type":"journal-article","created":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T23:14:52Z","timestamp":1635981292000},"page":"105466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Synthesis of aspirin-curcumin mimic conjugates of potential antitumor and anti-SARS-CoV-2 properties"],"prefix":"10.1016","volume":"117","author":[{"given":"Aladdin M.","family":"Srour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siva S.","family":"Panda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Fayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May A.","family":"El-Manawaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"A. F. Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yassmin","family":"Moatasim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"El Taweel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed F.","family":"Abdelhameed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed S.","family":"Bekheit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel S.","family":"Girgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bioorg.2021.105466_b0005","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.apsb.2016.06.003","article-title":"The modification of natural products for medical use","volume":"7","author":"Guo","year":"2017","journal-title":"Acta Pharm. Sinica B"},{"key":"10.1016\/j.bioorg.2021.105466_b0010","doi-asserted-by":"crossref","first-page":"13946","DOI":"10.1039\/c4ra00227j","article-title":"Recent developments in chemistry and biology of curcumin analogues","volume":"4","author":"Bairwa","year":"2014","journal-title":"RSC Adv."},{"issue":"7","key":"10.1016\/j.bioorg.2021.105466_b0015","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.bmcl.2016.02.066","article-title":"Biological evaluation and molecular docking studies of new curcuminoid derivatives: synthesis and characterization","volume":"26","author":"Banuppriya","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.bioorg.2021.105466_b0020","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/cbdd.13061","article-title":"Synthesis, evaluation of cytotoxic properties of promising curcumin analogues and investigation of possible molecular mechanisms","volume":"91","author":"Jordan","year":"2018","journal-title":"Chem. Biol. Drug Des."},{"issue":"92","key":"10.1016\/j.bioorg.2021.105466_b0025","doi-asserted-by":"crossref","first-page":"75575","DOI":"10.1039\/C5RA14925H","article-title":"Recent advances of curcumin and its analogues in breast cancer prevention and treatment","volume":"5","author":"Mock","year":"2015","journal-title":"RSC Adv."},{"issue":"58","key":"10.1016\/j.bioorg.2021.105466_b0030","doi-asserted-by":"crossref","first-page":"52905","DOI":"10.1039\/C6RA01515H","article-title":"Curcumin induces cell death of human papillary thyroid carcinoma BCPAP cells through endoplasmic reticulum stress","volume":"6","author":"Zhang","year":"2016","journal-title":"RSC Adv."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105466_b0035","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1128\/AAC.01238-06","article-title":"Cytotoxic effect of curcumin on malaria parasite Plasmodium falciparum: inhibition of histone acetylation and generation of reactive oxygen species","volume":"51","author":"Cui","year":"2007","journal-title":"Antimicrob. Agents Chemothe."},{"key":"10.1016\/j.bioorg.2021.105466_b0040","first-page":"1894","article-title":"Pharmacodynamic and pharmacokinetic study of oral curcuma extract in patients with colorectal cancer","volume":"7","author":"Sharma","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2021.105466_b0045","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejmech.2016.12.043","article-title":"Synthesis and biological evaluation of curcumin inspired indole analogues as tubulin polymerization inhibitors","volume":"127","author":"Sri Ramya","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"24","key":"10.1016\/j.bioorg.2021.105466_b0050","doi-asserted-by":"crossref","first-page":"5971","DOI":"10.1016\/j.bmcl.2016.10.080","article-title":"Synthesis and biological evaluation of allylated mono-carbonyl analogues of curcumin (MACs) as anti-cancer agents for cholangiocarcinoma","volume":"26","author":"Qiu","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2021.105466_b0055","doi-asserted-by":"crossref","unstructured":"P.K. Sahu, Design, structure activity relationship, cytotoxicity and evaluation of antioxidant activity of curcumin derivatives\/analogues. Eur. J. Med. Chem. 121 (2016) 510\u2013516. dx.doi.org\/10.1016\/j.ejmech.2016.05.037.","DOI":"10.1016\/j.ejmech.2016.05.037"},{"key":"10.1016\/j.bioorg.2021.105466_b0060","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.bmcl.2018.01.070","article-title":"Curcumin inspired 2-chloro\/phenoxy quinoline analogues: Synthesis and biological evaluation as potential anticancer agents","volume":"28","author":"Sri Ramya","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"10","key":"10.1016\/j.bioorg.2021.105466_b0065","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.bmcl.2016.03.092","article-title":"Synthesis of unsymmetrical monocarbonyl curcumin analogues with potent inhibition on prostaglandin E2 production in LPS-induced murine and human macrophages cell lines","volume":"26","author":"Mohd Aluwi","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"16","key":"10.1016\/j.bioorg.2021.105466_b0070","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1016\/j.bmc.2018.08.018","article-title":"Optimization of diarylpentadienones as chemotherapeutics for prostate cancer","volume":"26","author":"Patanapongpibul","year":"2018","journal-title":"Bioorg. Med. Chem."},{"issue":"58","key":"10.1016\/j.bioorg.2021.105466_b0075","doi-asserted-by":"crossref","first-page":"33761","DOI":"10.1039\/C9RA05661K","article-title":"Synthesis, human topoisomerase II\u03b1 inhibitory properties and molecular modeling studies of anti-proliferative curcumin mimics","volume":"9","author":"Fawzy","year":"2019","journal-title":"RSC Adv."},{"issue":"8","key":"10.1016\/j.bioorg.2021.105466_b0080","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.2174\/1871520619666190408131639","article-title":"Novel curcumin inspired antineoplastic 1-sulfonyl-4-piperidones: design, synthesis and molecular modeling studies","volume":"19","author":"Fawzy","year":"2019","journal-title":"Anti-Cancer Agents Med. Chem."},{"issue":"17","key":"10.1016\/j.bioorg.2021.105466_b0085","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1016\/j.bmcl.2016.07.053","article-title":"Synthesis and biological evaluation of some novel triazole hybrids of curcumin mimics and their selective anticancer activity against breast and prostate cancer cell lines","volume":"26","author":"Mandalapu","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"31","key":"10.1016\/j.bioorg.2021.105466_b0090","doi-asserted-by":"crossref","first-page":"26003","DOI":"10.1039\/C5RA25853G","article-title":"Discovery of monocarbonyl curcumin hybrids as a novel class of human DNA ligase I inhibitors: in silico design, synthesis and biology","volume":"6","author":"Mandalapu","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2021.105466_b0095","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1016\/j.ejmech.2011.03.060","article-title":"Curcumin analogues as possible anti-proliferative & anti-inflammatory agents","volume":"46","author":"Katsori","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105466_b0100","doi-asserted-by":"crossref","first-page":"114147","DOI":"10.1016\/j.bcp.2020.114147","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective","volume":"180","author":"Bindu","year":"2020","journal-title":"Biochem. Pharm."},{"key":"10.1016\/j.bioorg.2021.105466_b0105","doi-asserted-by":"crossref","unstructured":"C. Fiala, M.D. Pasic, Aspirin: Bitter pill or miracle drug?, Clin. Biochem. 85 (2020) 1\u20134. dx.doi.org\/10.1016\/j.bmcl.2016.07.053.","DOI":"10.1016\/j.clinbiochem.2020.07.003"},{"key":"10.1016\/j.bioorg.2021.105466_b0110","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomised trials of antiplatelet therapy. prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients","volume":"308","author":"Collaboration","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/j.bioorg.2021.105466_b0115","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.0306-5251.2001.01476.x","article-title":"Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies","volume":"52","author":"Garc\u00eda Rodr\u00edguez","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105466_b0120","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.ejmech.2010.11.032","article-title":"Synthesis and anti-inflammatory evaluation of some new acyl-hydrazones bearing 2-aryl-thiazole","volume":"46","author":"Moldovan","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105466_b0125","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1136\/bmj.321.7270.1183","article-title":"Risk of gastrointestinal haemorrhage with long term use of aspirin: meta\u00adanalysis","volume":"321","author":"Derry","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.bioorg.2021.105466_b0130","doi-asserted-by":"crossref","unstructured":"R. Jirm\u00e1\u0159, P. Widimsk\u00fd, Enteric-coated aspirin in cardiac patients: Is it less effective than plain aspirin?, Cor Vasa 60 (2018) e165\u2013e168. dx.doi.org\/10.1016\/j.crvasa.2017.05.011.","DOI":"10.1016\/j.crvasa.2017.05.011"},{"issue":"1","key":"10.1016\/j.bioorg.2021.105466_b0135","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/ijc.32083","article-title":"Long-term use of low-dose aspirin for cancer prevention: a 10-year population cohort study in Hong Kong","volume":"145","author":"Tsoi","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bioorg.2021.105466_b0140","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jamaoncol.2018.4154","article-title":"Association between aspirin use and risk of hepatocellular carcinoma","volume":"4","author":"Simon","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.bioorg.2021.105466_b0145","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jamaoncol.2018.4149","article-title":"Association of analgesic use with risk of ovarian cancer in the nurses\u2019 health studies","volume":"4","author":"Barnard","year":"2018","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.bioorg.2021.105466_b0150","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrc.2016.4","article-title":"Aspirin and colorectal cancer: the promise of precision chemoprevention","volume":"16","author":"Drew","year":"2016","journal-title":"Nat. Rev. Cancer."},{"key":"10.1016\/j.bioorg.2021.105466_b0155","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","article-title":"Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials","volume":"376","author":"Rothwell","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2021.105466_b0160","first-page":"1586","article-title":"Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer","volume":"11","author":"Johnson","year":"2002","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"5","key":"10.1016\/j.bioorg.2021.105466_b0165","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1470-2045(09)70035-X","article-title":"Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement","volume":"10","author":"Cuzick","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bioorg.2021.105466_b0170","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/23948","article-title":"The anti-inflammatory agents aspirin and salicylate inhibit the activity of I\u03baB kinase-\u03b2","volume":"396","author":"Yin","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2021.105466_b0175","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1126\/science.8052854","article-title":"Inhibition of NF-kappa B by sodium salicylate and aspirin","volume":"265","author":"Kopp","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2021.105466_b0180","doi-asserted-by":"crossref","first-page":"6494","DOI":"10.1021\/acs.jmedchem.5b00536","article-title":"Novel resveratrol-based aspirin prodrugs: synthesis, metabolism, and anticancer activity","volume":"58","author":"Zhu","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105466_b0185","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1186\/s12885-015-1868-7","article-title":"A novel aspirin prodrug inhibits NF\u03baB activity and breast cancer stem cell properties","volume":"15","author":"Kastrati","year":"2015","journal-title":"BMC Canc."},{"key":"10.1016\/j.bioorg.2021.105466_b0190","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejmech.2016.02.052","article-title":"Synthesis and biological evaluation of salicylic acid conjugated isoxazoline analogues on immune cell proliferation and angiogenesis","volume":"114","author":"Puttaswamy","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"20","key":"10.1016\/j.bioorg.2021.105466_b0195","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1016\/j.bmcl.2015.08.023","article-title":"Synthesis and anti-cancer potential of the positional isomers of NOSH-aspirin (NBS-1120) a dual nitric oxide and hydrogen sulfide releasing hybrid","volume":"25","author":"Vannini","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"7","key":"10.1016\/j.bioorg.2021.105466_b0200","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1002\/anie.201308899","article-title":"The prodrug platin-A: simultaneous release of cisplatin and aspirin","volume":"53","author":"Pathak","year":"2014","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.bioorg.2021.105466_b0205","doi-asserted-by":"crossref","first-page":"112200","DOI":"10.1016\/j.ejmech.2020.112200","article-title":"True or false? Challenges and recent highlights in the development of aspirin prodrugs","volume":"192","author":"Willetts","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"16","key":"10.1016\/j.bioorg.2021.105466_b0210","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/j.bmcl.2019.06.023","article-title":"SAR optimization studies on modified salicylamides as a potential treatment for acute myeloid leukemia through inhibition of the CREB pathway","volume":"29","author":"Chae","year":"2019","journal-title":"Bioorg. Med., Chem. Lett."},{"key":"10.1016\/j.bioorg.2021.105466_b0215","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejmech.2017.04.027","article-title":"Synthesis and antiproteasomal activity of novel O-benzyl salicylamide-based inhibitors built from leucine and phenylalanine","volume":"135","author":"Jorda","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"14","key":"10.1016\/j.bioorg.2021.105466_b0220","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1016\/j.bmc.2012.05.034","article-title":"Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC\u2013EGFR dual inhibitors","volume":"20","author":"Zuo","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105466_b0225","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3390\/ph11040101","article-title":"Cyclooxygenase-1 (COX-1) and COX-1 inhibitors in cancer: a review of oncology and medicinal chemistry literature","volume":"11","author":"Pannunzio","year":"2018","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2021.105466_b0230","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/md19010012","article-title":"Preparation, COX-2 inhibition and anticancer activity of sclerotiorin derivatives","volume":"19","author":"Chen","year":"2021","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.bioorg.2021.105466_b0235","doi-asserted-by":"crossref","first-page":"112812","DOI":"10.1016\/j.ejmech.2020.112812","article-title":"Recent progress in small molecule agents for the targeted therapy of triple-negative breast cancer","volume":"207","author":"Islam","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105466_b0240","doi-asserted-by":"crossref","first-page":"112954","DOI":"10.1016\/j.ejmech.2020.112954","article-title":"Small-molecule inhibitors of breast cancer-related targets: potential therapeutic agents for breast cancer","volume":"210","author":"Liu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2021.105466_b0245","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1039\/C4OB02149E","article-title":"Synthesis, and QSAR analysis of anti-oncological active spiro-alkaloids","volume":"13","author":"Girgis","year":"2015","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.bioorg.2021.105466_b0250","doi-asserted-by":"crossref","first-page":"153437","DOI":"10.1016\/j.prp.2021.153437","article-title":"LncRNA KLK8 modulates stem cell characteristics in colon cancer","volume":"224","author":"Wang","year":"2021","journal-title":"Pathol. \u2013 Res. Prac."},{"key":"10.1016\/j.bioorg.2021.105466_b0255","first-page":"75","article-title":"Colorectal cancer \u2013 review","volume":"100","author":"Haraldsdottir","year":"2014","journal-title":"Laeknabladid"},{"key":"10.1016\/j.bioorg.2021.105466_b0260","doi-asserted-by":"crossref","first-page":"112866","DOI":"10.1016\/j.ejmech.2020.112866","article-title":"Design, synthesis and structure-activity relationship study of novel urea compounds as FGFR1 inhibitors to treat metastatic triplenegative breast cancer","volume":"209","author":"Ashraf-Uz-Zaman","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105466_b0265","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3389\/fonc.2018.00227","article-title":"Recent advances in the treatment of breast cancer","volume":"8","author":"Tong","year":"2018","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.bioorg.2021.105466_b0270","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3109\/10731199.2010.494578","article-title":"Advances in novel drug delivery strategies for breast cancer therapy","volume":"38","author":"Dhankhar","year":"2010","journal-title":"Artif. Cells Blood Substit, Immobil. Biotechnol."},{"key":"10.1016\/j.bioorg.2021.105466_b0275","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13555-016-0165-y","article-title":"Skin cancer: epidemiology, disease burden, pathophysiology, diagnosis and therapeutic approaches","volume":"7","author":"Apalla","year":"2017","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.bioorg.2021.105466_b0280","first-page":"9","article-title":"Sun-protective behaviors in populations at high risk for skin cancer","volume":"7","author":"Diao","year":"2013","journal-title":"Psychol. Res. Behav. Manage."},{"key":"10.1016\/j.bioorg.2021.105466_b0285","doi-asserted-by":"crossref","first-page":"126755","DOI":"10.1016\/j.bmcl.2019.126755","article-title":"Synthesis and evaluation of 1,3,5-triazine derivatives as sunscreens useful to prevent skin cancer","volume":"29","author":"Reis","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2021.105466_b0290","doi-asserted-by":"crossref","first-page":"104595","DOI":"10.1016\/j.bioorg.2020.104595","article-title":"Synthesis, inverse docking-assisted identification and in vitro biological characterization of flavonol-based analogs of fisetin as c-Kit, CDK2 and mTOR inhibitors against melanoma and non-melanoma skin cancers","volume":"107","author":"Roy","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2021.105466_b0295","doi-asserted-by":"crossref","first-page":"104490","DOI":"10.1016\/j.bioorg.2020.104490","article-title":"Computational drug discovery and repurposing for the treatment of COVID-19: a systematic review","volume":"106","author":"Mohamed","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2021.105466_b0300","doi-asserted-by":"crossref","first-page":"112687","DOI":"10.1016\/j.ejmech.2020.112687","article-title":"Potential treatment methods targeting 2019-nCoV infection","volume":"205","author":"Zheng","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105466_b0305","unstructured":"https:\/\/covid19.who.int\/ (accessed on Sept. 23, 2021)."},{"key":"10.1016\/j.bioorg.2021.105466_b0310","doi-asserted-by":"crossref","first-page":"104315","DOI":"10.1016\/j.bioorg.2020.104315","article-title":"Role of heterocyclic compounds in SARS and SARS CoV-2 pandemic","volume":"104","author":"Negi","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2021.105466_b0315","doi-asserted-by":"crossref","first-page":"104326","DOI":"10.1016\/j.bioorg.2020.104326","article-title":"A perspective on potential target proteins of COVID-19: comparison with SARS-CoV for designing new small molecules","volume":"104","author":"Kumar","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2021.105466_b0320","doi-asserted-by":"crossref","first-page":"115860","DOI":"10.1016\/j.bmc.2020.115860","article-title":"Protease targeted COVID-19 drug discovery and its challenges: insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors","volume":"29","author":"Amin","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105466_b0325","doi-asserted-by":"crossref","first-page":"116040","DOI":"10.1016\/j.bmc.2021.116040","article-title":"Potential inhibitors interacting in Neuropilin-1 to develop an adjuvant drug against COVID-19, by molecular docking","volume":"33","author":"Vique-S\u00e1nchez","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105466_b0330","doi-asserted-by":"crossref","first-page":"113157","DOI":"10.1016\/j.ejmech.2021.113157","article-title":"Ahmad, The race to treat COVID-19: potential therapeutic agents for the prevention and treatment of SARS-CoV-2","volume":"213","author":"Shagufta","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105466_b0335","doi-asserted-by":"crossref","first-page":"104488","DOI":"10.1016\/j.bioorg.2020.104488","article-title":"Drug repurposing for the treatment of COVID-19: pharmacological aspects and synthetic approaches","volume":"106","author":"Batalha","year":"2021","journal-title":"Bioorg. Chem."},{"issue":"39","key":"10.1016\/j.bioorg.2021.105466_b0340","doi-asserted-by":"crossref","first-page":"23379","DOI":"10.1039\/D0RA03774E","article-title":"Natural products' role against COVID-19","volume":"10","author":"Antonio","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2021.105466_b0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2020.05.027","article-title":"Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: what can we safely use?","volume":"136","author":"Gougis","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.bioorg.2021.105466_b0350","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1158\/2159-8290.CD-21-0144","article-title":"Repurposing of anticancer drugs expands possibilities for antiviral and anti-inflammatory discovery in COVID-19","volume":"11","author":"Aldea","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2021.105466_b0355","doi-asserted-by":"crossref","first-page":"113267","DOI":"10.1016\/j.ejmech.2021.113267","article-title":"A new class of \u03b1-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities","volume":"215","author":"Wang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105466_b0360","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13046-015-0199-5","article-title":"Therapeutic potential of antiviral drugs targeting chemorefractory colorectal adenocarcinoma cells overexpressing endogenous retroviral elements","volume":"34","author":"D\u00edaz-Carballo","year":"2015","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2021.105466_b0365","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3390\/ph13120443","article-title":"FDA-approved drugs with potent in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2","volume":"13","author":"Mostafa","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2021.105466_b0370","first-page":"929","article-title":"Synthesis of novel SN38-aspirin prodrugs for the treatment of hepatocellular carcinoma","volume":"42","author":"Chen","year":"2018","journal-title":"Turk. J. Chem."},{"key":"10.1016\/j.bioorg.2021.105466_b0375","doi-asserted-by":"crossref","unstructured":"V.U. Jeankumar, M. Chandran, G. Samala, M. Alvala, P.V. Koushik, P. Yogeeswari, E.G. Salina, D. Sriram, Development of 5-nitrothiazole derivatives: Identification of leads against both replicative and latent Mycobacterium tuberculosis, Bioorg. Med. Chem. Lett. 22 (2012) 7414\u20137417. dx.doi.org\/10.1016\/j.bmcl.2012.10.060.","DOI":"10.1016\/j.bmcl.2012.10.060"},{"issue":"6","key":"10.1016\/j.bioorg.2021.105466_b0380","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/j.bmc.2011.01.047","article-title":"Synthesis, biological evaluation and 3D-QSAR studies of 3-keto salicylic acid chalcones and related amides as novel HIV-1 integrase inhibitors","volume":"19","author":"Sharma","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105466_b0385","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1021\/jm0002580","article-title":"A conformational and structure-activity relationship study of cytotoxic 3,5-bis(arylidene)-4-piperidones and related N-acryloyl analogues","volume":"44","author":"Dimmock","year":"2001","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2021.105466_b0390","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1016\/j.bmc.2013.03.057","article-title":"Discovery and evaluation of piperid-4-one-containing mono-carbonyl analogs of curcumin as anti-inflammatory agents","volume":"21","author":"Wu","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105466_b0395","doi-asserted-by":"crossref","first-page":"105131","DOI":"10.1016\/j.bioorg.2021.105131","article-title":"3-Alkenyl-2-oxindoles: synthesis, antiproliferative and antiviral properties against SARS-CoV-2","volume":"114","author":"Girgis","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2021.105466_b0400","unstructured":"https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/fluorouracil."},{"key":"10.1016\/j.bioorg.2021.105466_b0405","unstructured":"https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/fluorouracil-topical."},{"key":"10.1016\/j.bioorg.2021.105466_b0410","unstructured":"https:\/\/www.drugs.com\/history\/sutent.html."},{"key":"10.1016\/j.bioorg.2021.105466_b0415","unstructured":"https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/sunitinibmalate."},{"issue":"3","key":"10.1016\/j.bioorg.2021.105466_b0420","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/nprot.2006.238","article-title":"Analysis of apoptosis by propidium iodide staining and flow cytometry","volume":"1","author":"Riccardi","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.bioorg.2021.105466_b0425","doi-asserted-by":"crossref","first-page":"105117","DOI":"10.1016\/j.bioorg.2021.105117","article-title":"New quinoline-triazole conjugates: synthesis, and antiviral properties against SARS-CoV-2","volume":"114","author":"Seliem","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2021.105466_b0430","unstructured":"I.A. Seliem, A.S. Girgis, Y. Moatasim, A. Kandeil, A. Mostafa, M.A. Ali, M.S. Bekheit, S.S. Panda, New pyrazine conjugates: Synthesis, computational studies, and antiviral properties against SARS-CoV-2. ChemMedChem (in press). doi.org\/10.1002\/cmdc.202100476."},{"key":"10.1016\/j.bioorg.2021.105466_b0435","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3390\/cancers10070224","article-title":"Current molecular-targeted therapies in NSCLC and their mechanism of resistance","volume":"10","author":"Schrank","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"15","key":"10.1016\/j.bioorg.2021.105466_b0440","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.4155\/fmc-2018-0416","article-title":"Thiazole in the targeted anticancer drug discovery","volume":"11","author":"Ayati","year":"2019","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105466_b0445","doi-asserted-by":"crossref","first-page":"105011","DOI":"10.1016\/j.bioorg.2021.105011","article-title":"The synthesis review of the approved Tyrosine kinase inhibitors for anticancer therapy in 2015\u20132020","volume":"113","author":"Liang","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2021.105466_b0450","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.2174\/1568026617666170707124126","article-title":"Multi-targeted anticancer agents","volume":"17","author":"Zheng","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105466_b0455","doi-asserted-by":"crossref","unstructured":"R.-g. Fu, Y. Sun, W.-b. Sheng, D.-f. Liao, Designing multi-targeted agents: An emerging anticancer drug discovery paradigm, Eur. J. Med. Chem. 136 (2017) 195\u2013211. dx.doi.org\/10.1016\/j.ejmech.2017.05.016.","DOI":"10.1016\/j.ejmech.2017.05.016"},{"key":"10.1016\/j.bioorg.2021.105466_b0460","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1021\/jm030427r","article-title":"Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-Phenyl-N\u02c8-{4-(4-quinolyloxy)phenyl}ureas","volume":"48","author":"Kubo","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105466_b0465","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/1947601911423031","article-title":"Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies","volume":"2","author":"Shibuya","year":"2011","journal-title":"Genes & Cancer"},{"key":"10.1016\/j.bioorg.2021.105466_b0470","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrm1911","article-title":"VEGF receptor signaling in control of vascular function","volume":"7","author":"Olsson","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.bioorg.2021.105466_b0475","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1021\/acs.jmedchem.7b01091","article-title":"Discovery of novel potent VEGFR-2 inhibitors exerting significant antiproliferative activity against cancer cell lines","volume":"61","author":"Zhang","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105466_b0480","first-page":"123","article-title":"Clinical advances in the development of novel VEGFR2 inhibitors","volume":"2","author":"Fontanella","year":"2014","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.bioorg.2021.105466_b0485","unstructured":"Santa Cruz Biotechnology, Inc., Oregon, USA, VEGFR2 (A-3): sc-6251 (www.scbt.com)."},{"key":"10.1016\/j.bioorg.2021.105466_b0490","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cellsig.2018.07.010","article-title":"Advances in targeting epidermal growth factor receptor signaling pathway in mammary cancer","volume":"51","author":"Kyriakopoulou","year":"2018","journal-title":"Cell. Signal."},{"issue":"3","key":"10.1016\/j.bioorg.2021.105466_b0495","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ccr.2014.02.025","article-title":"ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics","volume":"25","author":"Arteaga","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2021.105466_b0500","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.3390\/ijms18112420","article-title":"Molecular-targeted therapies for epidermal growth factor receptor and its resistance mechanisms","volume":"18","author":"Yamaoka","year":"2017","journal-title":"Inter. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2021.105466_b0505","unstructured":"Santa Cruz Biotechnology, Inc., Oregon, USA, EGFR (528): sc-120 (www.scbt.com)."},{"issue":"6","key":"10.1016\/j.bioorg.2021.105466_b0510","doi-asserted-by":"crossref","first-page":"7204","DOI":"10.18632\/oncotarget.23208","article-title":"Inflammatory responses and inflammation-associated diseases in organs","volume":"9","author":"Chen","year":"2018","journal-title":"Oncotarget 9"},{"issue":"7","key":"10.1016\/j.bioorg.2021.105466_b0515","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/nrrheum.2015.40","article-title":"Atherosclerosis in rheumatoid arthritis: is it all about inflammation?","volume":"11","author":"Skeoch","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.bioorg.2021.105466_b0520","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nri3786","article-title":"Type 2 inflammation in asthmadpresent in most, absent in many","volume":"15","author":"Fahy","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"6917","key":"10.1016\/j.bioorg.2021.105466_b0525","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"issue":"2010","key":"10.1016\/j.bioorg.2021.105466_b0530","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.cell.2010.03.006","article-title":"Inflammation: new adventures of an old flame","volume":"140","author":"Medzhitov","year":"2010","journal-title":"Cell"},{"issue":"16","key":"10.1016\/j.bioorg.2021.105466_b0535","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1016\/j.bmc.2017.06.027","article-title":"Design, synthesis, and biological evaluation of some novel indolizine derivatives as dual cyclooxygenase and lipoxygenase inhibitor for anti-inflammatory activity","volume":"25","author":"Shrivastava","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105466_b0540","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1124\/pr.56.3.3","article-title":"Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition","volume":"56","author":"Simmons","year":"2004","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bioorg.2021.105466_b0545","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.bmc.2009.02.057","article-title":"Phenolic compounds with radical scavenging and cyclooxygenase-2 (COX-2) inhibitory activities from Dioscorea opposite","volume":"17","author":"Yang","year":"2009","journal-title":"Bioorg. Med. Chem."},{"issue":"21","key":"10.1016\/j.bioorg.2021.105466_b0550","doi-asserted-by":"crossref","first-page":"6745","DOI":"10.1016\/j.bmcl.2012.08.082","article-title":"Synthesis and pharmacological evaluation of N-substituted 2-(2-oxo-2H-chromen-4-yloxy)propanamide as cyclooxygenase inhibitors","volume":"22","author":"Rambabu","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2021.105466_b0555","unstructured":"COX-1 Inhibitor Screening Kit (Fluorometric), Catalog#K548-100, BioVision Incorporated, CA 95035 USA, www.biovision.com."},{"key":"10.1016\/j.bioorg.2021.105466_b0560","unstructured":"COX-2 Inhibitor Screening Kit (Fluorometric), Catalog#K547-100, BioVision Incorporated, CA 95035 USA, www.biovision.com."},{"key":"10.1016\/j.bioorg.2021.105466_b0565","unstructured":"Discovery Studio 2.5, Accelrys Software Inc. (http:\/\/www.accelrys.com)."},{"key":"10.1016\/j.bioorg.2021.105466_b0570","unstructured":"https:\/\/www.rcsb.org\/structure\/4G5P."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105466_b0575","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/jpet.112.197756","article-title":"Target binding properties and cellular activity of Afatinib (BIBW 2992), an irreversible ErbB family blocker","volume":"343","author":"Solca","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bioorg.2021.105466_b0580","unstructured":"https:\/\/www.drugs.com\/history\/gilotrif.html."},{"key":"10.1016\/j.bioorg.2021.105466_b0585","unstructured":"https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-drug\/def\/afatinib-dimaleate."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206821008440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206821008440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:29:53Z","timestamp":1758616193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206821008440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":117,"alternative-id":["S0045206821008440"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.105466","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis of aspirin-curcumin mimic conjugates of potential antitumor and anti-SARS-CoV-2 properties","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.105466","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105466"}}